Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Katsuyuki Furuta"'
Autor:
Eriko Murakami, Hiroaki Akamatsu, Shunsuke Teraoka, Toshiaki Takakura, Eri Takase, Masanori Tanaka, Takahiro Kaki, Yuhei Harutani, Katsuyuki Furuta, Takeya Sugimoto, Ryota Shibaki, Daichi Fujimoto, Atsushi Hayata, Yuichi Ozawa, Masanori Nakanishi, Yasuhiro Koh, Toshio Shimokawa, Nobuyuki Yamamoto
Publikováno v:
Cancer Medicine, Vol 13, Iss 4, Pp n/a-n/a (2024)
Abstract Background Mannitol is exclusively recommended in the National Comprehensive Cancer Network guidelines for diuresis in cisplatin (CDDP)‐based chemotherapy. The utility of furosemide, a widely used and convenient diuretic, thus requires cla
Externí odkaz:
https://doaj.org/article/936934c8acbe4ec093a80de605ccb236
Autor:
Mihoko Imaji, Daichi Fujimoto, Mai Kato, Masanori Tanaka, Katsuyuki Furuta, Nobuyuki Yamamoto
Publikováno v:
Respirology Case Reports, Vol 9, Iss 5, Pp n/a-n/a (2021)
Abstract Little is known about the safety of chemotherapy plus atezolizumab for patients with extensive‐stage small cell lung cancer (ES‐SCLC) undergoing haemodialysis (HD). An 80‐year‐old male received carboplatin [area under the concentrati
Externí odkaz:
https://doaj.org/article/c652cc982232455080dfdc0724ee89ca
Autor:
Katsuyuki Furuta, Hiroaki Akamatsu, Ryuichi Sada, Kyohei Miyamoto, Shunsuke Teraoka, Atsushi Hayata, Yuichi Ozawa, Masanori Nakanishi, Yasuhiro Koh, Nobuyuki Yamamoto
Publikováno v:
Acute Medicine & Surgery, Vol 8, Iss 1, Pp n/a-n/a (2021)
Aim The emergency department requires simple and useful clinical indicators to identify bacteremia. This retrospective study explored the Systemic Inflammatory Response Syndrome (SIRS) and quick Sequential Organ Failure Assessment (qSOFA) scores for
Externí odkaz:
https://doaj.org/article/1b0bd88407f2442dad2339088b14c235
Autor:
Eri Takase, Hiroaki Akamatsu, Shunsuke Teraoka, Keita Nakaguchi, Masanori Tanaka, Takahiro Kaki, Katsuyuki Furuta, Koichi Sato, Eriko Murakami, Takeya Sugimoto, Ryota Shibaki, Daichi Fujimoto, Atsushi Hayata, Nahomi Tokudome, Yuichi Ozawa, Yasuhiro Koh, Masanori Nakanishi, Kuninobu Kanai, Toshio Shimokawa, Nobuyuki Yamamoto
Background: The efficacy and tolerability of high-flow nasal cannula (HFNC) for relieving dyspnea in advanced cancer patients with limited prognosis requires elucidation. Methods: Patients with advanced cancer who had dyspnea at rest (numeric rating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::053072e04eee67e8700506ed3cf47b14
https://doi.org/10.21203/rs.3.rs-2639256/v1
https://doi.org/10.21203/rs.3.rs-2639256/v1
Autor:
Katsuyuki Furuta, Daichi Fujimoto, Atsushi Matsunashi, Takeshi Morimoto, Masanori Tanaka, Ryota Shibaki, Yuri Shimada, Kazuma Nagata, Keisuke Tomii, Nobuyuki Yamamoto
No large-scale studies have reported on the clinical course of acute exacerbation of fibrosing interstitial lung disease (AE-FILD). We aimed to elucidate the clinical course of AE-FILD. We retrospectively included patients admitted with AE-FILD diagn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7012a2886ac5674c8f038850e0baed8
https://doi.org/10.21203/rs.3.rs-1658658/v1
https://doi.org/10.21203/rs.3.rs-1658658/v1
Autor:
Yuri Shimada, Masanori Tanaka, Keisuke Tomii, Ryota Shibaki, Kazuma Nagata, Daichi Fujimoto, Nobuyuki Yamamoto, Atsushi Matsunashi, Katsuyuki Furuta
Publikováno v:
ILD / DPLD of known origin.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1414f9915661fe95c2de295c57f04c9
https://doi.org/10.1183/13993003.congress-2021.pa2241
https://doi.org/10.1183/13993003.congress-2021.pa2241
Autor:
Nahomi Tokudome, Nobuyuki Yamamoto, Eri Takase, Atsushi Hayata, Eriko Murakami, Yuichi Ozawa, Masanori Tanaka, Ryota Shibaki, Shunsuke Teraoka, Takeya Sugimoto, Takahiro Kaki, Nao Yamagata, Jun Oyanagi, Yasuhiro Koh, Katsuyuki Furuta, Hiroaki Akamatsu, Keita Mori, Yuhei Harutani, Yuka Okuda
Publikováno v:
The Oncologist
Background Although predictive value of immune‐related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) have been suggested by several studies, their assessments were insufficient because patients were categorized only by the o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7352b560f7a3ac0bcb3cbba9bd7b6739
https://doi.org/10.1634/theoncologist.2019-0299
https://doi.org/10.1634/theoncologist.2019-0299
Autor:
Yuhei Harutani, Yuichi Ozawa, Eriko Murakami, Koichi Sato, Jun Oyanagi, Hiroaki Akamatsu, Takanori Yoshikawa, Ryota Shibaki, Takeya Sugimoto, Katsuyuki Furuta, Shunsuke Teraoka, Nahomi Tokudome, Atsushi Hayata, Hiroki Ueda, Masanori Nakanishi, Yasuhiro Koh, Nobuyuki Yamamoto
Publikováno v:
Cancer immunology, immunotherapy : CII. 71(9)
While PD-1/L1 inhibitors are characterized by durable tumor control, they also prolong survival without prolongation of progression-free survival (PFS) in part of patients. However, little is known about the factors and mechanisms involved in this. B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4408f16c1a3de647fb466744ec400833
https://pubmed.ncbi.nlm.nih.gov/35037070
https://pubmed.ncbi.nlm.nih.gov/35037070
Autor:
Hiroaki Akamatsu, Yasuhiro Koh, Katsuyuki Furuta, Kyohei Miyamoto, Atsushi Hayata, Nobuyuki Yamamoto, Masanori Nakanishi, Shunsuke Teraoka, Yuichi Ozawa, Ryuichi Sada
Publikováno v:
Acute Medicine & Surgery
Acute Medicine & Surgery, Vol 8, Iss 1, Pp n/a-n/a (2021)
Acute Medicine & Surgery, Vol 8, Iss 1, Pp n/a-n/a (2021)
Aim The emergency department requires simple and useful clinical indicators to identify bacteremia. This retrospective study explored the Systemic Inflammatory Response Syndrome (SIRS) and quick Sequential Organ Failure Assessment (qSOFA) scores for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62e53e732663ca4c0fd4927ada508bc5
http://europepmc.org/articles/PMC8088398
http://europepmc.org/articles/PMC8088398
Publikováno v:
Respirology Case Reports, Vol 9, Iss 5, Pp n/a-n/a (2021)
Respirology Case Reports
Respirology Case Reports
Little is known about the safety of chemotherapy plus atezolizumab for patients with extensive‐stage small cell lung cancer (ES‐SCLC) undergoing haemodialysis (HD). An 80‐year‐old male received carboplatin [area under the concentration‐time
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc0b50e3586a7b939dde8871d844c2d7
https://doi.org/10.1002/rcr2.741
https://doi.org/10.1002/rcr2.741